Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Non-Current Liabilities (2022 - 2025)

Historic Total Non-Current Liabilities for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $130.1 million.

  • BioXcel Therapeutics' Total Non-Current Liabilities fell 4.0% to $130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.1 million, marking a year-over-year decrease of 4.0%. This contributed to the annual value of $124.8 million for FY2024, which is 272.71% down from last year.
  • BioXcel Therapeutics' Total Non-Current Liabilities amounted to $130.1 million in Q3 2025, which was down 4.0% from $130.8 million recorded in Q2 2025.
  • BioXcel Therapeutics' Total Non-Current Liabilities' 5-year high stood at $139.0 million during Q3 2023, with a 5-year trough of $82.0 million in Q2 2022.
  • Over the past 4 years, BioXcel Therapeutics' median Total Non-Current Liabilities value was $129.2 million (recorded in 2023), while the average stood at $125.3 million.
  • Per our database at Business Quant, BioXcel Therapeutics' Total Non-Current Liabilities surged by 6119.07% in 2023 and then crashed by 638.14% in 2024.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Total Non-Current Liabilities stood at $126.7 million in 2022, then increased by 1.24% to $128.3 million in 2023, then fell by 2.73% to $124.8 million in 2024, then grew by 4.25% to $130.1 million in 2025.
  • Its Total Non-Current Liabilities was $130.1 million in Q3 2025, compared to $130.8 million in Q2 2025 and $125.5 million in Q1 2025.